Viz.ai drives upsell via algorithms

This is what turns Viz.ai from a single use stroke tool into a hospital wide software account. Once a health system has the mobile workflow, image routing, and specialist call tree running for stroke, adding a new algorithm for pulmonary embolism or hypertrophic cardiomyopathy means selling another alert and triage pathway into the same screens, users, and IT setup. That raises revenue per customer without forcing the hospital to rip out or relearn the core workflow.1 2 3 4 5

• The product expansion is concrete, not theoretical. Viz.ai had 12 FDA approved algorithms across stroke, pulmonary embolism, and hypertrophic cardiomyopathy by 2023. The HCM product, for example, scans routine ECGs, flags likely cases, then sends cardiologists into the same mobile coordination flow used elsewhere on the platform.1 3 4 5
• The land point is usually stroke because the ROI is easy to see. Viz.ai built early fit in primary stroke centers, where faster large vessel occlusion detection cuts transfer and notification times and can increase thrombectomy volume at hub hospitals. That proof makes it easier to sell adjacent modules to the same neurology, radiology, and cardiology buyers.2 6
• Competitors are expanding the same way, which makes breadth matter. Aidoc had 23 FDA clearances as of May 2024, and RapidAI also added an FDA cleared pulmonary embolism product. In practice, hospitals comparing vendors are not just buying one algorithm, they are buying the vendor that can cover the most urgent service lines on one workflow backbone.2 8

The next leg is deeper enterprise standardization. As Viz.ai adds more disease pathways, the buying decision shifts from a department level imaging tool to a system level care coordination platform, with more modules, more specialists, and more annual contract value attached to the same hospital relationship.1 2 5